Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engert

Showing results (101-110 of 173) with videos related to

Pageof 18
Sort By:
Nuklearmedizin. Nuclear Medicine|December 6, 2008
[FDG-PET in Hodgkin lymphoma]C Kobe, M Dietlein, C Mauz-Körholz, et al.
International Journal of Molecular Medicine|September 18, 2004
Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell linesA Rothe, A Klimka, M K Tur, et al.
Leukemia|January 19, 2000
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxinR Schnell, E Vitetta, J Schindler, et al.
Leukemia & Lymphoma|December 30, 1998
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphomaM Reiser, R Schnell, G Straub, et al.
Cancer Research|May 1, 1997
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cellsH Bohlen, O Manzke, S Titzer, et al.
Seminars in Oncology|October 1, 1993
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study GroupW Hiddemann, M Unterhalt, C Pott, et al.
Der Pathologe|December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]P Borchmann, K Behringer, A Josting, et al.
International Journal of Molecular Medicine|October 18, 2001
An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell linesM K Tur, S Sasse, M Stöcker, et al.
Blood|January 15, 1994
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxinsU Winkler, C Gottstein, G Schön, et al.
Leukemia & Lymphoma|March 18, 2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Pageof 18

Showing results (101-110 of 173) with videos related to

Sort By:
Pageof 18
Nuklearmedizin. Nuclear Medicine|December 6, 2008
[FDG-PET in Hodgkin lymphoma]C Kobe, M Dietlein, C Mauz-Körholz, et al.
International Journal of Molecular Medicine|September 18, 2004
Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell linesA Rothe, A Klimka, M K Tur, et al.
Leukemia|January 19, 2000
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxinR Schnell, E Vitetta, J Schindler, et al.
Leukemia & Lymphoma|December 30, 1998
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphomaM Reiser, R Schnell, G Straub, et al.
Cancer Research|May 1, 1997
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cellsH Bohlen, O Manzke, S Titzer, et al.
Seminars in Oncology|October 1, 1993
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study GroupW Hiddemann, M Unterhalt, C Pott, et al.
Der Pathologe|December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]P Borchmann, K Behringer, A Josting, et al.
International Journal of Molecular Medicine|October 18, 2001
An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell linesM K Tur, S Sasse, M Stöcker, et al.
Blood|January 15, 1994
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxinsU Winkler, C Gottstein, G Schön, et al.
Leukemia & Lymphoma|March 18, 2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Pageof 18